- Home
- CYRX vs PRTA Comparison
CYRX vs PRTA Comparison
Compare CYRX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | PRTA |
|---|---|---|
| Founded | 1999 | 2012 |
| Country | United States | Ireland |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.6M | 482.3M |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CYRX | PRTA |
|---|---|---|
| Price | $8.05 | $9.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $12.94 | ★ $19.00 |
| AVG Volume (30 Days) | 341.9K | ★ 387.4K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $176,177,000.00 | $814,000.00 |
| Revenue This Year | $9.71 | $1,395.77 |
| Revenue Next Year | $9.56 | N/A |
| P/E Ratio | $4.99 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.63 | $4.32 |
| 52 Week High | $11.45 | $15.14 |
Technical Indicators
Market Signals| Indicator | CYRX | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.26 | 56.40 |
| Support Level | $6.57 | $8.23 |
| Resistance Level | $8.45 | $9.59 |
| Average True Range (ATR) | 0.51 | 0.56 |
| MACD | 0.04 | 0.10 |
| Stochastic Oscillator | 25.71 | 71.21 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a leader serving the life sciences industry as a provider of integrated temperature-controlled supply chain solutions supporting the life sciences in the biopharma/pharma, animal health, and reproductive medicine markets. It operates in two reportable segments: Life Sciences Services and Life Sciences Products. Geographically the company operates in the Americas, Europe, the Middle East and Africa (EMEA), and Asia Pacific (APAC), generating a majority of its revenue from the Americas.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.